Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
Authors:
Top Cited Papers
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Mark Foundation For Cancer Research (23-034-ASP)
- Mark Foundation For Cancer Research (21-029-ASP)
- Imperial Experimental Cancer Medicine Centre
- Canadian Institutes of Health Research
- European Research Council
- Royal Society (211179/Z/18/Z)
- Francis Crick Institute (CC2041)
- Wellcome Trust
- Horizon 2020 Framework Programme (835297)
- Rosetrees Trust
- Stoneygate Trust
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Novo Nordisk Foundation Center for Basic Metabolic Research (RF\\ERE\\231118)
- Novo Nordisk Foundation Center for Basic Metabolic Research (ID16584)
- Novo Nordisk Foundation Center for Basic Metabolic Research (RP/EA/180007)
- Breast Cancer Research Foundation (EDDPMA-Nov21/100034)
- Breast Cancer Research Foundation (BCRF-23-157)
- Medical Research Council (C416/A21999)
- UCLH Biomedical Research Centre
- Japan Society for the Promotion of Science (202060447)
- Cancer Research UK (C11496/A17786)
- Cancer Research UK (C11496/A30025)
This publication has 40 references indexed in Scilit:
- Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung CancerJAMA Oncology, 2024
- Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancerTrends in Cancer, 2024
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2024
- Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancerCancer Cell, 2023
- Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2023
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancerAnnals of Oncology, 2022
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsyMolecular Oncology, 2020
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature, 2017